Traditional multiplexed bulk assays, flow cytometry, and genomics miss critical functional immune cell attributes, thus hiding the true identity of each cell.
IsoPlexis provides the missing insights into the in vivo biology required to advance medicines & diagnostics.
Our Single-Cell Functional Proteomics technology reveals the rare subsets of highly-polyfunctional cells that simultaneously secrete multiple cytokines.
These supercells are predictive of patient response and disease progression in vivo and are responsible for orchestrating immune responses and accelerating the development of advanced, curative medicine
SUPERHUMAN BIOLOGY
Single-cell Functional Proteomics Revealing Superhero Cells in the Proteomics Landscape
Traditional technologies like bulk ELISA, Genomics, and Flow Cytometry can estimate cellular function at the population level, but these estimates do not reflect differences in that population's function.
We developed the only technology able to phenotype each immune cell by its extracellular function, revealing the unique power of the individual supercell.
Only IsoPlexis captures the highly multiplexed cytokine signatures from each cell, revealing the unique power of the individual supercell.
IsoPlexis' functional difference reveals the highly proteomically multi-functional superhero immune cells that orchestrate immune response. The presence of these cells is a key predictor of early and persistent response to cancer, efficacy of vaccines, and overall survival, as published in various high impact journals.
Superhuman Cell Biology Has Been Published in 100+ Publications
01
Key Takeaways
Traditional technology misses the critical functional attributes that only IsoPlexis' unique superpowered biology can reveal.
IsoPlexis' functional difference uniquely reveals the highly proteomically multi-functional superhero immune cells that orchestrate immune response.
Superhero cells are key predictors of early and persistent response to cancer, efficacy of vaccines, and overall survival, as published in various high impact journals.
Overview
Unmask the Supercells in Your Research
IsoPlexis uniquely reveals superhuman cells— highly polyfunctional cells that are early actors and orchestrators in the immune response. These rare subsets of highly functional cells can be beneficial (superheroes) or detrimental (supervillains). Detecting these cells is critical for the development of more effective immune therapies and vaccines.
Supercells Unmasked
Superhero Cells
Superhero cells are rare subsets of highly polyfunctional "super cells" that orchestrate the response against tumors and correlate to potency, persistence, and survival.
Supervillain Cells
Supervillain cells are highly polyfunctional "super cells" that drive disease progression and correlate to inflammation, toxicity, and resistance.
Why Proteome is Critical
to Superhero Cells
The proteome is complex and requires direct detection. Dynamic in vivo biology is the captured by the proteome— the key to advancing medicines and diagnostics.
Unique Superhero Cells are Key
to Fighting Cancer
By uniquely highly multiplexing the cytokines, chemokines, and phosphoproteins from each cell, IsoPlexis technology is able to uniquely reveal the orchestrator supercells — the 5-10% of cells that are early actors in immune response
02
Key Takeaways
Polyfunctional cells secrete many different cytokines simultaneously and have correlated with outcome in multiple studies.
Only IsoPlexis can detect the true functional single-cell cytokine secretions correlative to response.
Overview
Our Leap in Innovation
IsoPlexis' breakthrough single-cell functional phenotyping technology tells you exactly what each immune cell functionally produces with a range of 30+ cytokines. This leap in innovation allows researchers to phenotype each immune cell by its extracellular function.
OUR INNOVATIVE TECHNOLOGY
Why Understanding Single Cell
Function is Critical
Cytokine function dictates the response of each cell to the tumor:
- CD4 T cells: Cytokines orchestrate the rest of the cells to attack the tumor
- CD8 T cells & NK Cells: Cytokines deliver the payload to the tumor
- Macrophages & T-Reg: Cytokines drive immune suppression in the tumor
Immune
Cells
Cells
Immune
Cells
Cells
Tumor
Directly Detect the Functional Cytokines
of Each Immune Cell
Each immune cell is different, thus the complete characterization of each individual cell is critical.
While transcriptome is measured via RNA seq, and surface phenotype is measured via flow cytometry, the complete cellular definition is incomplete without measuring extracellular cytokines that are doing the work in tumor immunology.
For single cells, we're filling a gap as the only technology to do something very, obviously critical — directly detecting the functional cytokines that matter.
1
1
Functional Phenotype
SC Secretome
2
Functional Phenotype
SC Signaling
A breakthrough Technological Innovation
IsoPlexis' Innovation in Cellular
Analysis: the IsoCode Chip
Our proprietary & patented “Proteomic Barcoded” IsoCode Chip, named the Scientist's number #1 innovation, works by detecting 30+ cytokines per cell, measuring the functional phenotype of each immune cell.
This breakthrough technical innovation allows for complete single-cell functional characterization — something that was not possible before.
03
Key Takeaways
ELISA & Flow Cytometry can estimate a sample's cytokine secretion, but cannot detect the highly functional cell subsets that correlate to in vivo response.
RNA-Seq can estimate function as well, but only shows a 0.4 correlation from RNA to protein.
Only IsoPlexis can detect the highly-potent single-cell subsets by capturing the range of cytokines (32+) from each cell.
Overview
What's Unique & Innovative about
IsoPlexis Single-Cell Functional Phenotyping?
Unlike IsoPlexis, these traditional methods are unable to detect the functional biological drivers that can lead to biomarker breakthroughs.
The IsoPlexis Difference
TRUE SINGLE T CELL BIOLOGY
IsoPlexis' Breakthrough Technology
Our technology addresses the core problem that immune cells, which play a major role in cancer immunology, are heterogenous.
IsoPlexis enables researchers to fine-tune their immunotherapeutic candidates and identify what differentiates immune cell potency, cell product toxicity, and functional differences between patient responders and non-responders to immunotherapies.
COMPARISON
Traditional Methods vs IsoPlexis
Bulk Serum ELISA Averaging
Bulk Averaging
Traditional Method
Bulk Serum ELISA Averaging
Data shows that the specific cytokines produced by each heterogenous immune cell matters, yet bulk averaging masks these cellular differences.
Bulk ELISA averages serum protein information from all cells. In a variety of immunotherapy trials, stratification of responders from non-responders is not possible with bulk cytokine analysis.
Single Cell Cytokine Specificity
The IsoPlexis Difference
IsoPLexis
IsoPlexis
Our single-cell functional proteomics uniquely reveal correlates that lead to biomarker breakthroughs by detecting what each immune cell secretes in a highly multiplexed manner.
- Captures the true single-cell protein secretion with 30+ plex full range of function
- Detects how immune cells proteomically perform amongst a heterogenous system
- Reveals functional biological drivers that identify patient differences
Flow Cytometry & RNA
Estimates
Traditional Method
Flow Cytometry Based Systems
Flow cytometry “surface phenotypes” for many surface markers or detects a few (1-4) blocked cytokines within the cell without detecting what's truly being secreted.
Blocking cytokines within cells increases the risk of spectral overlap and reduces the ability to multiplex cytokines reliably.
RNA-Seq based methods estimate protein function, yet are not protein measurements, with citations showing 0.4 correlation from RNA to protein1.
Reference [1]: Vogel at al. Nature Reviews Genetics (2012)
True, Highly Multiplexed Cytokines Released
The IsoPlexis Difference
IsoPLexis
IsoPlexis
Our unique functional phenotyping is directly measuring the work performed by each T cell, macrophage, or NK cell.
Each IsoCode Chip is proteomically barcoded to provide a quantitative readout of 32 cytokines per cell.
This unique functional phenotyping provides correlative clinical & pre-clinical immune biomarkers for differentiating mechanistic information in the competitive clinical world of immuno-oncology.
04
Key Takeaways
IsoSpeak enables researchers to make sense of complex single-cell data by automatically generating intuitive and meaningful visualizations.
Researches can save precious time by using the in-software sample annotations & project organization for immunotherapy workflows.
IsoSpeak helps you get answers faster, with detailed informatics & statistics on cellular potency and durability, all at your fingertips.
Overview
Single-Cell Cytokine
Visualizations & Insights
IsoSpeak is the first automated informatics suite for advanced, functional, single-cell mapping and visualizations which can reveal correlative insights into true, functional immune biology.
Researchers use IsoSpeak to make sense of complex single-cell data by generating meaningful visualizations with the click of a button.
IsoSpeak's push-button user interface and advanced automation allows users to visualize, target, and utilize data from direct, functional cytokine profiling of single cells.
SOFTWARE
IsoSpeak Data
Visualizations
Researchers can use IsoSpeak to automatically generate a unique set of cellular visualizations, sample annotations, and report-ready single-cell readouts.
05
Key Takeaways
We've worked hand-in-hand with the pioneers in immunology to discover correlates that were previously hidden.
Our discoveries continue to be published in leading journals such as Nature, Cancer Discovery, JITC, and Blood.
The IsoLight is the new standard found throughout the most innovative labs around the world.
Overview
Publications
IsoPlexis' functional phenotyping is critical to finding what's really happening in patients — as shown in 40+ correlative cancer immunology cases. Our functional phenotypes are illustrating the large patient differences between different types of patient responses that are undetectable on other platforms.
INSIGHTS
IsoPlexis is Uniquely Revealing the Biological Drivers of Response and Progression
IsoPlexis' functional phenotyping has been published and presented by leaders in various clinical and preclinical studies.
Additionally, we've translated that insight to accelerate pre-clinical development — illustrating large differences leading to choice.
PUBLICATIONS
Published in 100+ High-Impact Journals
Our superhuman biology helps researchers around the world change the course of advanced medicines and complex diseases.
2022
VACCINES & INFECTIOUS DISEASE
Li L et al., "In-depth analysis of SARS-CoV-2-specific T cells reveals diverse differentiation hierarchies in vaccinated individuals", JCI Insight, 2022
CELLULAR AND REGENERATIVE MEDICINE
Fernandez-Yague MA et al., "Analyzing immune response to engineered hydrogels by hierarchical clustering of inflammatory cell subsets", Science Advances, 2022
Cancer Immunology
Friedman et al., "Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses", Journal for ImmunoTherapy of Cancer, 2022
VACCINES & INFECTIOUS DISEASE
Su Yet al., "Multiple Early Factors Anticipate Post-Acute COVID-19 Sequelae", Cell, 2022
2021
CELLULAR AND REGENERATIVE MEDICINE
Thomas A et al., "Benign tumors in TSC are amenable to treatment by GD3 CAR T cells in mice", JCI Insight, 2021
CELLULAR AND REGENERATIVE MEDICINE
Roselli E et al., "4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells", Journal for ImmunoTherapy of Cancer, 2021
Cancer Immunology
Abbas H et al., "Single-cell Polyfunctional Proteomics of CD4 Cells from Patients with AML Predicts Responses to Anti-PD-1-based therapy", Blood Advances, 2021
CELLULAR AND REGENERATIVE MEDICINE
Gionet-Gonzales M et al., "Sulfated Alginate Hydrogels Prolong the Therapeutic Potential of MSC Spheroids by Sequestering the Secretome", Advanced Healthcare Materials, 2021
Cancer Immunology
Creelan BC et al., "Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial", Nature Medicine, 2021
Cellular and Regenerative Medicine
Spiegel JY et al., "CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase I trial", Nature Medicine, 2021
Cancer Immunology
Dhar P et al., "Tumor-derived NKG2D ligand sMIC reprograms NK cells to an inflammatory phenotype through CBM signalosome activation", Communications Biology, 2021
Cancer Immunology
Dhar P et al., "Tumor-derived NKG2D ligand sMIC reprograms NK cells to an inflammatory phenotype through CBM signalosome activation", Communications Biology, 2021
Cancer Immunology
Boklee J et al., "Venetoclax enhances T cell-mediated antileukemic activity by increasing ROS production", Blood, 2021
Cancer Immunology
Diab A et al., "Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma", Journal of Clinical Oncology, 2021
Cellular and Regenerative Medicine
Chockley P et al., "Transient blockade of TBK1/IKKε allows efficient transduction of primary human natural killer cells with vesicular stomatitis virus G-pseudotyped lentiviral vectors", Cytotherapy, 2021
Cancer Immunology
Mahmoud A et al., "Synchronous effects of targeted mitochondrial complex I inhibitors on tumor and immune cells abrogate melanoma progression", iScience, 2021
Cancer Immunology, Cellular and Regenerative Medicine
Ruiz F et al., "Comprehensive Activation Profiling of Tabelecleucel, an Off-The-Shelf, Allogeneic EBV-Specific T-Cell Immunotherapy", Hematological Oncology, 2021
Cancer Immunology
Vicioso Y et al., "NF-κB c-Rel Is Dispensable for the Development but Is Required for the Cytotoxic Function of NK Cells", Frontiers in Immunology, 2021
Vaccines & Infectious Disease
Szabo PA et al., "Longitudinal profiling of respiratory and systemic immune responses reveals myeloid cell-driven lung inflammation in severe COVID-19", Immunity, 2021
Cellular and Regenerative Medicine
McKenna MK et al., "Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity", Molecular Therapy, 2021
Oncology
Patel RR et al., "Use of Multi-Site Radiation Therapy for Systemic Disease Control", International Journal of Radiation Oncology*Biology*Physics. 2021., 2021
Cellular and Regenerative Medicine
Xie CB et al., "Complement‐activated human endothelial cells stimulate increased polyfunctionality in alloreactive T cells", American Journal of Transplantation, 2021
Our Biology
The New Standard in
Single-Cell Biology
We help researchers around the world accelerate the next generation of cancer immunotherapy with functional immunology.
"Quality assays are mainly descriptive with some objective parameters like cytokine production, cytotoxicity, and proliferation. Only recently, with PSI… can we start to differentiate products."
Moffitt Cancer Center
"As a cancer research center with a key focus on CAR-T and other cell therapies, we feel that IsoPlexis will enable us to better characterize response and potentially predict whether cancer patients will respond to CAR-T
therapy before
treatment."
City of Hope
"Current assays that rely on single-plex ELISA or even multiparametric flow cytometry don't give you the level of resolution that the IsoPlexis platform can provide."
Kite Pharma
"Quality assays are mainly descriptive with some objective parameters like cytokine production, cytotoxicity, and proliferation. Only recently, with PSI… can we start to differentiate products."
Moffitt Cancer Center
"As a cancer research center with a key focus on CAR-T and other cell therapies, we feel that IsoPlexis will enable us to better characterize response and potentially predict whether cancer patients will respond to CAR-T
therapy before
treatment."
City of Hope
"Current assays that rely on single-plex ELISA or even multiparametric flow cytometry don't give you the level of resolution that the IsoPlexis platform can provide."
Kite Pharma
06
The Superhuman Cell Company
Join researchers worldwide using IsoPlexis to reclaim lab time, save precious samples, increase efficacy, and cut down therapeutic timelines by a year+.
Advance Research & Medicines Across Applications
Gain deeper access to in vivo biology through highly multiplexed single-cell proteomics & transcriptomics.
Generate Publication-Ready Visualizations
Instantly analyze, dissect, visualize, and export your data with a click of a button — no coding required.
Save Time with Walk-Away Automation
Fully automate your workflow with our all-in-one, intuitive system that fits on your lab bench.
EXPAND
Cytokines Define Cell Function
PAT-PCA
HEATMAP
PSI
